Gary S. Gillheeney - May 23, 2022 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Signature
/s/ William R. Kolb, Attorney-in-Fact
Stock symbol
ORGO
Transactions as of
May 23, 2022
Transactions value $
-$925,194
Form type
4
Date filed
5/25/2022, 06:18 PM
Previous filing
May 20, 2022
Next filing
May 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORGO Class A Common Stock Options Exercise $6.6K +6.67K +1.67% $0.99 405K May 23, 2022 Direct
transaction ORGO Class A Common Stock Options Exercise $53.1K +53.7K +13.26% $0.99 459K May 23, 2022 Direct
transaction ORGO Class A Common Stock Sale -$39K -6.67K -1.45% $5.84 452K May 23, 2022 Direct F1, F2
transaction ORGO Class A Common Stock Sale -$311K -53.7K -11.88% $5.80 398K May 23, 2022 Direct F1, F3
transaction ORGO Class A Common Stock Options Exercise $51.8K +52.3K +13.14% $0.99 451K May 24, 2022 Direct
transaction ORGO Class A Common Stock Sale -$296K -52.3K -11.61% $5.66 398K May 24, 2022 Direct F1, F4
transaction ORGO Class A Common Stock Options Exercise $83.8K +84.7K +21.26% $0.99 483K May 25, 2022 Direct
transaction ORGO Class A Common Stock Sale -$474K -84.7K -17.53% $5.60 398K May 25, 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -6.67K -0.62% $0.00 1.07M May 23, 2022 Class A Common Stock 6.67K $0.99 Direct F6
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -53.7K -8.07% $0.00 611K May 23, 2022 Class A Common Stock 53.7K $0.99 Direct F6
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -52.3K -8.56% $0.00 559K May 24, 2022 Class A Common Stock 52.3K $0.99 Direct F6
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -84.7K -15.15% $0.00 474K May 25, 2022 Class A Common Stock 84.7K $0.99 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.70 to $6.05, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.705 to $5.93, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.60 to $5.73, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.47 to $5.72, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
F6 100% of the shares subject to the option are fully vested and exercisable.